TABLE 1.
Clinical characteristics of patients involved in the study.
| Characteristics | Training cohort (TARGET-OS, n = 88) | Validation cohort (GSE21257, n = 53) | |
| Age | |||
| < 14 | 39(44.32%) | 15 (28.3%) | |
| =14 | 45(51.14%) | 38 (71.7%) | |
| Unknown | 4 (4.55%) | 0 | |
| Gender | |||
| Female | 37 (42.05%) | 19 (35.85%) | |
| Male | 47 (53.41%) | 34 (64.15%) | |
| Unknown | 4 (4.55%) | 0 | |
| Race | |||
| Non-White | 13 (14.77%) | NA | |
| White | 51 (57.95%) | NA | |
| Unknown | 24 (27.27%) | NA | |
| Ethnicity | |||
| Not Hispanic or Latino | 52 (59.09%) | NA | |
| Hispanic or Latino | 11 (12.5%) | NA | |
| Unknown | 25 (28.41%) | NA | |
| Tumor location | |||
| Femur | NA | 27 (50.94%) | |
| Fibula | NA | 2 (3.77%) | |
| Humerus | NA | 8 (15.09%) | |
| Tibia | NA | 15 (28.3%) | |
| Unknown | NA | 1 (1.89%) | |
| Histological subtype | |||
| Chondroblastic | NA | 6 (11.32%) | |
| Fibroblastic | NA | 5 (9.43%) | |
| Osteoblastic | NA | 32 (60.38%) | |
| Others | NA | 10 (18.87%) | |
| Metastatic status | |||
| Non-metastatic | 63 (71.59%) | 39 (73.58%) | |
| Metastatic | 21 (23.86%) | 14 (26.42%) | |
| Unknown | 4 (4.55%) | 0 | |
| Survival status | |||
| Alive | 58 (65.91%) | 30 (56.6%) | |
| Dead | 27 (30.68%) | 23 (43.4%) | |
| Unknown | 3 (3.41%) | 0 | |